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LGR5 expression is regulated by EGF in early
colorectal adenomas and governs EGFR
inhibitor sensitivity
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1School of Cellular and Molecular Medicine, University of Bristol, Biomedical Sciences Building, University Walk, Bristol BS8
1TD, UK and 2European Cancer Stem Cell Research Institute, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff
CF24 4HQ, UK
Background: LGR5 serves as a co-receptor for Wnt/b-catenin signalling and marks normal intestinal stem cells; however, its role in
colorectal cancer (CRC) remains controversial. LGR5þ cells are known to exist outside the stem cell niche during CRC progression,
and the requirement for epidermal growth factor (EGF) signalling within early adenomas remains to be fully elucidated.
Methods: Epidermal growth factor and gefitinib treatments were performed in EGF-responsive LGR5þ early adenoma
RG/C2 cells. 2D growth assays were measured using an IncuCyte. LGR5 or MEK1/2 silencing studies were executed using siRNA
and LGR5 expression was assessed by qRT–PCR and immunoblotting. Ki67 level and cell cycle status were analysed by flow
cytometry.
Results: Epidermal growth factor suppresses expression of LGR5 at both the transcript and protein level in colorectal adenoma
and carcinoma cells. Suppression of LGR5 reduces the survival of EGF-treated adenoma cells by increasing detached cell yield but
also inducing a proliferative state, as evidenced by elevated Ki67 level and enhanced cell cycle progression. Repression of LGR5
further increases the sensitivity of adenoma cells to EGFR inhibition.
Conclusions: LGR5 has an important role in the EGF-mediated survival and proliferation of early adenoma cells and could have
clinical utility in predicting response of CRC patients to EGFR therapy.
Colorectal cancer (CRC) is one of the most common cancers of the
developed world (Ferlay et al, 2015) and progresses through a well-
defined adenoma-carcinoma sequence (Fearon and Vogelstein,
1990). During malignant transformation, a tumour must adopt a
variety of phenotypic states including inhibition of proliferation to
promote survival, in order to respond and persist under various
selection pressures (e.g., resource deprivation, immune predation
or drug exposure) (Aktipis et al, 2013). Understanding how cancer
cells are able to arrest growth in order to adapt to environmental
insult is crucial in order to successfully treat CRC. Our previous
work has shown that LGR5 (leucine-rich G-protein coupled
receptor 5, Gpr49) serves as a pro-survival factor in early
human colorectal adenoma cells (Al-Kharusi et al, 2013). LGR5
is a seven-transmembrane receptor protein that potentiates
canonical Wnt signalling and is itself a downstream Wnt target
gene, while also marking normal stem cells in multiple tissue types,
including the colon (Barker et al, 2007). The advent of 3D organoid
culture has shown that single isolated LGR5þ cells from the gut
form self-organising crypt/villus structures that harbour the full
repertoire of differentiated epithelial lineages of the intestine (Sato
et al, 2009). Epidermal growth factor (EGF) is secreted by the
Paneth cells in the niche to maintain LGR5þ stem cells (Sato et al,
2011b), and forms an essential component of organoid medium for
the establishment of normal isolated LGR5þ stem cells in 3D
culture (Sato et al, 2009). Studies examining the function of LGR5
in CRC cells have produced confusing and contradictory results,
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with some studies suggestive of a pro-tumourigenic role for LGR5
(Hirsch et al, 2014; Liu et al, 2014; Lin et al, 2015) while others
indicate a tumour-suppressive role (de Sousa et al, 2011; Walker
et al, 2011; Wu et al, 2014). Regardless of the ‘top-down’ or
‘bottom-up’ theories that have been proposed for CRC initiation
(Shih et al, 2001; Preston et al, 2003), colorectal adenomas are
known to harbour LGR5þ cells (Baker et al, 2015; Yanai et al,
2017). Furthermore, in mouse intestinal adenomas, it has been
shown that LGR5þ cells are intermingled with Paneth cells in
architecture reminiscent of the normal crypt which indicates
LGR5þ cells remain dependent on secreted factors during early
tumourigenesis (Schepers et al, 2012). The specific requirements
for EGF signalling at this stage are not fully understood. EGF
signalling is a critical pathway for normal intestinal homeostasis,
and amplification or mutations to the EGF receptor (EGFR) or
downstream signalling components such as KRAS are frequent in
CRC and render promising EGFR therapies ineffective (Moroni
et al, 2005; Lievre et al, 2006; van Houdt et al, 2010; Misale et al,
2012). However, there remains considerable variability in the
clinical response of CRC patients to EGFR inhibition (EGFRi)
despite wild-type KRAS or EGFR status, meaning additional factors
can dictate EGFRi sensitivity (Blanke, 2005; Jimeno et al, 2009;
Shaib et al, 2013). Our study shows for the first time that EGF
exposure represses LGR5 expression in human colorectal adenoma
and tumour cells at both the protein and transcriptional level.
Furthermore, LGR5 silencing in adenoma cells enhances the
proliferative state of EGF-treated adenoma cells, as observed by
induction of Ki67 expression, enhanced cell cycle progression and
reduced survival. Such observations suggest the modulation of
LGR5 expression is important for directing the proliferative/
survival phenotypes necessary for adenoma cell adaptation to
environmental pressures. Importantly, the knockdown of LGR5
increases the sensitivity of adenoma cells to the EGFR inhibitor
gefitinib, suggesting low LGR5 expression could be used clinically
to predict patients who may benefit from EGFR therapies.
MATERIALS AND METHODS
Cell culture and treatments. The colorectal adenoma cell line
RG/C2 was maintained as previously described (Al-Kharusi et al,
2013). For 2D growth measurements, RG/C2 adenoma cells were
seeded at 1.25 104 cells per well of a 96-well plate and treated
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Figure 1. LGR5 is suppressed in EGF-responsive RG/C2 adenoma cells. (A) Representative IncuCyte images showing confluence of RG/C2 2D cell
culture at 48 h þ / EGF (50ngml 1). (B) Summary graph showing RG/C2 cell 2D growth rate over 48 h þ / EGF. (C) Representative widefield
microscopy images of RG/C2 adenoma spheroid morphology at 8, 15 and 22 days post-seeding following culture in 3D þ / EGF (50ngml 1).
White scale bar indicates 250mm. (D) Summary of average RG/C2 adenoma spheroid diameter following 8, 15 and 22 days post-seeding in 3D
culture þ / EGF (50ngml 1). (E) Immunoblot showing expression of pERK1/2 and LGR5 protein in RG/C2 adenoma cells with a dose-response
of EGF treatment. Statistical significance is denoted by ***Po0.001.
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with vehicle control (water) or 5, 10, 25 and 50 ngml 1 EGF
(Peprotech, London, UK) for 72 h. Prior to all EGF or gefitinib
exposures, RG/C2 cells were grown in reduced serum (10% FBS)
for 16 h. For siRNA experiments, RG/C2 cells were seeded at
5 105 per ml and supplemented with either 2.5 ngml 1 EGF or
5mM gefitinib. For 3D culture 5 102 RG/C2 cells were seeded into
50 ml matrigel (Becton Dickinson, Oxford, UK) per well of a 24-
well plate and bathed in medium previously optimised for colonic
organoids (Sato et al, 2011a).
Imaging. Widefield imaging of 3D cultures was performed in situ
using a Leica DMI6000 inverted epifluorescence microscope (Leica,
Buckinghamshire, UK) with a Leica DFC365FX monochrome
digital camera in conjunction with LAS-X (Leica) acquisition
software version 1.1.0.12420. Multiple fields were captured in a
Z-stack through the matrigel and a minimum of 50 adenoma
spheroids measured at their widest diameter using LAS AF
software v2.6.0 (Leica). Post-acquisition refinement was performed
using Photoshop CS6 v13.0 (Adobe, Berkshire, UK). For 2D
growth assays, live real-time IncuCyte ZOOM software analysis
masks (Essen BioScience, Ltd., Welwyn Garden City,
Hertfordshire, UK) were used to measure cell growth. Data shown
are from six replicates (24 images per time-point).
Immunoblotting. LGR5 and a-tubulin immunoblotting was
performed as previously described (Al-Kharusi et al, 2013).
Antibodies were also used to EGFR, pEGFR, pERK1/2, LRP6,
Frizzled-5, Axin-2, Survivin, CyclinD1, MEK1/2 (Cell Signaling
Technology, Danvers, MA, USA), active b-catenin (Millipore,
Billerica, MA, USA), and c-MYC (Santa Cruz Biotechnology,
Dallas, TX, USA). All immunoblots shown are representative of
three independent experiments and a-tubulin was used to assess
protein loading.
qRT–PCR. LGR5 qRT–PCR was performed as previously
described (Al-Kharusi et al, 2013).
RNA interference. LGR5 knockdown was performed using
smartpool siRNA (GE Dharmacon, Buckinghamshire, UK) as
previously described (Al-Kharusi et al, 2013). MEK1 knockdown
was performed using smartpool siRNAs containing the following
four target sequences; 50-GCACAUGGAUGGAGGUUCU-30,
50-GCAGAGAGAGCAGAUUUGA-30, 50-GAGCAGAUUUGAA
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Figure 2. EGF represses LGR5 expression, partly through MEK1/2. (A) Representative immunoblot showing expression of LGR5 and pERK1/2
proteins in response to EGF time-course treatment (2.5 ngml1) of RG/C2 adenoma cells. (B) Representative immunoblot demonstrating LGR5
and pERK1/2 protein expression 24h following EGF (50 ngml 1) withdrawal from RG/C2 cells cultured in 3D for 22 days. (C) Summary of relative
LGR5 mRNA level in RG/C2 adenoma cells following 8, 24, 48 and 72h EGF treatment. (D) Representative immunoblots showing LGR5 protein
expression in response to 48 h treatment with dose-response of combined MEK1 and MEK2 siRNA. (E) Representative immunoblots showing
expression of various Wnt components and target genes in response to EGF time-course treatment (2.5 ngml 1) of RG/C2 adenoma cells
(in samples from A). Statistical significance is denoted by *Po0.05, **Po0.01.
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GCAACU-30 and 50-CCAGAAAGCUAAUUCAUCU-30 (GE
Dharmacon). MEK2 knockdown was performed using smartpool
siRNAs containing the following four target sequences; 50-CAAA
GACGAUGACUUCGAA-30, 50-GAUCAGCAUUUGCAUGGAA-
30, 50-GGAAGCUGAUCCACCUUGA-30 and 50-GAAAGUCAG-
CAUCGCGGUU-30 (GE Dharmacon).
Flow cytometric assessment of Ki67 and DNA content. For flow
cytometric analyses, 5 105 RG/C2 cells were trypsinised into
single cell suspensions, washed in staining buffer (1 PBS with
0.5% BSA) and fixed in 70% ice-cold ethanol. Following washing,
cells were incubated with PE-conjugated Ki67 antibody, or the
relevant isotype and concentration matched isotype control (BD)
for 30min. Following incubation, cells were washed and finally
resuspended in staining buffer containing 2 ml ml 1 DRAQ5
(Ebioscience, Altrincham, UK). Flow cytometric measurements
were acquired and analysed as previously described (Morgan et al,
2015).
Statistics. All statistical analyses were performed using GraphPad
Prism v7.0 (GraphPad Software, Inc., San Diego, CA, USA).
Significance of difference was assessed using a one-sample or
students t-test with significance defined at Po0.05. Unless
otherwise stated all data represent mean±1 standard deviation,
n¼ 3. Statistical significance is denoted by *Po0.05, **Po0.01,
***Po0.001 or n.s.¼ not significant.
RESULTS
LGR5 is suppressed in EGF-responsive RG/C2 adenoma cells.
To assess the effect of EGF on LGR5þ cells at an early stage of
CRC we required a physiologically relevant in vitro adenoma
model that exhibited EGF-sensitivity. For this we utilised the RG/
C2 adenoma cell line (KRASwt) which harbours high levels of
LGR5. Figure 1A and B demonstrate that the growth rate of RG/C2
adenoma cells in 2D is markedly enhanced in the presence of EGF
over 72 h. Similar to normal primary murine intestinal LGR5þ
cells (Sato et al, 2009), Figure 1C and D show RG/C2 adenoma
cells are highly dependent on EGF supplementation for establish-
ment and growth in 3D culture. In addition, RG/C2 adenoma
spheroids behave similarly to LGR5þ cells in 3D culture, in that
they exhibit enhanced differentiation-like features (branched/
budding morphology) upon removal of the p38 MAPK inhibitor
SB202190 from the medium (Supplementary Figure S1) (Otsuka
et al, 2010; Sato et al, 2011a). EGF is a potent mitogen with activity
in pico- and nanomolar ranges (Krall et al, 2011). To ascertain the
concentration of EGF required for EGFR pathway activation in
RG/C2 adenoma cells, we performed an EGF dose response over
24 h (Figure 1E). We observed that EGF treatment down to
2.5 ngml 1 was sufficient to activate EGFR signalling in these cells
as evidenced by optimal pERK1/2 induction. Perhaps unexpect-
edly, given the documented dependence of LGR5þ cells on EGF,
we observed that EGF treatment suppressed LGR5 protein
expression in adenoma cells at all EGF concentrations tested.
EGF represses both LGR5 protein and mRNA expression. Given
that we have previously demonstrated a short half-life for the
LGR5 protein (Morgan et al, 2015), we further characterised the
timing of LGR5 protein regulation by EGF in RG/C2 cells at
multiple early time-points by immunoblotting. Figure 2A shows
marked LGR5 suppression occurring as early as 4 h of EGF
exposure. To assess LGR5 regulation by EGF within 3D adenoma
culture, EGF was withdrawn for 24 h following 21 days culture in
standard EGF/Noggin/R-Spondin (ENR) medium (since RG/C2
cells are exquisitely dependent on EGF for establishment in 3D
culture) and LGR5 protein level was determined by immunoblot-
ting. As predicted from 2D observations, EGF withdrawal from
established 3D culture led to increased LGR5 expression in RG/C2
spheroids (Figure 2B). To understand the mechanism through
which EGF regulates LGR5, we analysed LGR5 mRNA levels in
RG/C2 cells following 8, 24, 48 and 72 h EGF treatment. Figure 2C
demonstrates how LGR5 mRNA is significantly repressed at 8 and
24 h EGF treatment, and remains suppressed at 48 and 72 h
(although this did not reach statistical significance). We also
observed EGF-mediated suppression of LGR5 protein and/or
mRNA expression at these same time-points in two CRC cell lines,
SW620 and LoVo (Supplementary Figure S2). Of note, this
regulation was not as marked as observed in the EGF-responsive
RG/C2 cell line perhaps due to the presence of KRAS mutations
and dysregulation of EGF signalling in these cell lines.
LGR5 is partly regulated through MEK/ERK signalling. Since
EGF activates MEK/ERK signalling (Figure 1E) (Giambartolomei
et al, 2001), we silenced the key signalling intermediary proteins
MEK1 and MEK2 in combination and subsequently examined
LGR5 expression. Figure 2D demonstrates efficient knockdown of
MEK1/2 proteins at 48 h at all siRNA concentrations assessed. In
agreement with EGF exposure (MEK1/2 activation) repressing
LGR5 protein expression, we observed that silencing of MEK1/2
proteins caused a consistent increase in LGR5 protein expression.
Given that LGR5 is a Wnt target gene (Barker et al, 2007), and
crosstalk exists between EGFR and Wnt/b-catenin signalling
pathways (Hu and Li, 2010), we examined whether EGF regulation
of LGR5 was indirect through inhibition of Wnt signalling. EGF-
treated RG/C2 samples from Figure 2A were assessed for
expression of Wnt signalling protein and target genes by
immunoblotting. Figure 2E shows no significant alteration in
Wnt signalling components or target genes was observed during
EGF treatment. These data suggest that EGF could negatively
regulate LGR5 expression in human colorectal adenoma cells in
part through activation of MEK/ERK signalling.
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LGR5 repression reduces survival and enhances proliferative
state of EGF-treated adenoma cells. To understand the functional
relevance of EGF-mediated suppression of LGR5, we adopted an
LGR5 siRNA approach. Figure 3A shows similar LGR5 suppres-
sion upon EGF treatment (as previously observed in Figures 1
and 2), and confirms efficient knockdown of LGR5 protein with
siRNA transfection at 24 h. To assess the impact of LGR5
knockdown on cell survival we measured detached floating
adenoma cell yield as a measurement of cell death. Consistent
with LGR5 being a pro-survival factor (Al-Kharusi et al, 2013), we
observed a significant increase in detached cell yield at both 24 and
48 h following LGR5 siRNA transfection (Figure 3B and C).
EGF treatment did not affect detached cell yield at 24 h but did
result in a significantly lower number of apoptotic cells at 48 h as
previously reported in the colon (Karnes et al, 1998; Suzuki et al,
2010). Finally, silencing of LGR5 increased the number of
apoptotic cells present in EGF treated cultures at 24 h and
significantly at 48 h.
To understand the basis for the reduced survival of EGF-treated
adenoma cells upon LGR5 knockdown, we next examined
expression levels of the Ki67 proliferation marker. EGF-
treated adenoma cells exhibited a significantly higher level of
Ki67 protein at both 24 and 48 h relative to control (Figure 4A
and B) as expected given the growth response of RG/C2 cells
to this mitogen (Figure 1A and B). Interestingly, at 24 and 48 h
time-points, suppression of LGR5 expression in the EGF-
treated cells significantly increased the level of Ki67 compared to
control and EGF-treated cells alone. To understand the basis for
the heightened proliferative state of EGF-treated adenoma
cells upon LGR5 suppression, we next analysed cell cycle status.
EGF-treated adenoma cultures contained a significantly higher
proportion of cells in the S-phase or G2/M stages of the cell
cycle, relative to control siRNA-treated cultures at both 24 and 48 h
(Figure 4C–E). In keeping with Ki67 measurements, the combina-
tion of EGF and LGR5 siRNA significantly increased the
proportion of cells in S-phase or G2/M stages of the cell cycle
compared with the control or EGF alone, at both 24 and 48 h.
Taken together these data indicate that suppression of
LGR5 enhances the proliferative capacity of EGF-treated adenoma
cells.
LGR5 repression increases the sensitivity of adenoma cells to
EGFR inhibition. Given the enhanced proliferative response to
EGF with LGR5 silencing, we next investigated whether this could
sensitise adenoma cells to EGFRi. To examine this, we used LGR5
siRNA in combination with the EGFR inhibitor gefitinib (trade name
Iressa). Western blot confirmed efficient LGR5 protein knockdown at
both 24 and 48h, and gefitinib efficiency with reduced pERK1/2
levels (Figure 5A). As observed from Figure 5B, EGFRi resulted in a
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small but significant reduction in the attached cell yield over 24 h,
which was significantly augmented by the suppression of LGR5.
A similar result was obtained following 48 h exposure of gefitinib,
albeit a higher degree of growth inhibition had occurred in the EGFRi
cultures, and significantly more with the combination of EGFRi- and
LGR5 RNAi-treated cultures (Figure 5C). Detached cell yield was
higher in RG/C2 adenoma cells treated with EGFRi but this was
significantly enhanced by combination with LGR5 siRNA at both 24
and 48h (Figure 5D and E).
DISCUSSION
Epidermal growth factor is an essential mitogen for the growth,
survival and development of the normal intestine. Detailed
analyses of the crypt base have shown neighbouring Paneth cells
secrete EGF to maintain the LGR5þ stem cell pool, while the
advent of organoid culture has demonstrated EGF to be one of the
essential components required for the survival and maintenance of
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intestinal stem cells in vitro (Sato et al, 2009, 2011b). A recent
study by Basak et al reported that EGF withdrawal from the ENR
medium abolished the proliferation of LGR5þ cells, induced
quiescence (via reduced MEK signalling), and led to a twofold
increase in LGR5 expression in normal primary mouse organoids
(Basak et al, 2017). Our study examined the dependence of early
human colorectal adenoma cells to EGF and compliments the
above report by showing that the dependence on EGF for the
proliferation of LGR5+ cells is retained by adenomas. Similar to
normal murine organoids, we noted an increase in LGR5
expression following EGF withdrawal from 3D adenoma culture
medium (Figure 2B). We also found EGF-mediated suppression of
LGR5 to occur through a MEK1/2-associated mechanism as
supported by the findings of another study where induced BRAF
mutations (MAPK activation) led to loss of LGR5 expression and
the intestinal stem cell pool (Riemer et al, 2015).
The majority of our study was performed in a single human
adenoma cell line (RG/C2); however, given the technical challenge
of obtaining early human adenoma tissue that has not yet accrued
RAS, RAF or EGFR mutations (which affect EGF signalling), this
model remains a valued resource for studying the early molecular
changes that occur during colonic adenoma progression. To
improve our understanding of the EGF–LGR5 axis for human
colorectal adenoma progression, further studies could be per-
formed in a primary organoid culture system where the stepwise
accumulation of genetic mutations essential for colorectal trans-
formation (e.g., APC, KRAS, P53, SMAD4) can be controlled
(Drost et al, 2015; Matano et al, 2015). Nether-the-less, these
results build on our previous identification of LGR5 as a pro-
survival factor in PGE2-treated adenoma cells (Al-Kharusi et al,
2013) and indicate that lowering of LGR5 expression could be an
important event for adenoma-carcinoma progression. Indeed, the
majority of adenoma cell lines contain high LGR5 expression,
while most carcinoma cell lines exhibit low or absent LGR5 (except
for metastatic cell lines) (Al-Kharusi et al, 2013)). De Sousa et al
showed in primary CRC tissue that loss of Wnt target gene
expression such as LGR5 was frequent during adenoma-carcinoma
progression (de Sousa et al, 2011) and other studies have reported
pro-proliferative states upon LGR5 reduction (Walker et al, 2011).
This fits too with the normal physiology of the intestinal crypt
since LGR5 expression is lost as stem cells exit the niche and
generate rapidly cycling progeny within the transit amplifying zone
(Barker et al, 2007). The re-emergence of LGR5 expression in
metastatic cell lines has perhaps recently been explained by de
Sousa and colleagues, where LGR5þ cells were dispensable for an
already established colorectal tumour, but were required for re-
establishment (and survival) of the tumour at a distant site (Melo
et al, 2017).
Vitally, our studies have also indicated a novel role for LGR5
expression in the sensitivity of adenoma cells to EGFR inhibitors
such as gefitinib. The proliferative response increased by LGR5
suppression potentiates EGFRi sensitivity and death of adenoma
cells (in keeping with the proliferative capacity of aggressive
tumours rendering them more sensitive to anticancer agents
(Valeriote and van Putten, 1975)). Gefitinib has previously shown
promise as a combinatorial agent to existing chemotherapeutic
regimens for CRC (Kuo et al, 2005; Ogino et al, 2005; Fisher et al,
2008). However, a longstanding clinical challenge has been the
heterogeneous response of CRC patients to EGFRi despite wild-
type EGFR or KRAS status (Blanke, 2005; Jimeno et al, 2009; Shaib
et al, 2013). This implies the contribution of additional factors to
EGFRi sensitivity and this study suggests tumours with low LGR5
expression will exhibit increased sensitivity. Given that EGFR has
recently been identified as a biomarker at the adenoma stage for
more aggressive CRC progression (Williet et al, 2017), our findings
suggest that there could also be clinical benefit in assessing LGR5
expression at this early stage in order to stratify those patients who
may respond best to EGFR therapy. LGR5 inhibitors have not been
reported, but our data would suggest a combinatorial approach
with EGFRi may synergise to reduce the survival of CRC cells.
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